Reversible hypogonadotropic hypogonadism in men with the fertile eunuch/Pasqualini syndrome: A single-center natural history study.

Kallmann syndrome genetics hypogonadotropic hypogonadism male infertility puberty reproduction reversible hypogonadism

Journal

Frontiers in endocrinology
ISSN: 1664-2392
Titre abrégé: Front Endocrinol (Lausanne)
Pays: Switzerland
ID NLM: 101555782

Informations de publication

Date de publication:
2022
Historique:
received: 26 09 2022
accepted: 13 10 2022
entrez: 21 11 2022
pubmed: 22 11 2022
medline: 23 11 2022
Statut: epublish

Résumé

Congenital hypogonadotropic hypogonadism (HH) is a heterogeneous genetic disorder characterized by disrupted puberty and infertility. In most cases, HH is abiding yet 10-15% undergo reversal. Men with HH and absent and partial puberty (i.e., testicular volume <4mL and >4mL respectively) have been well-studied, but the rare fertile eunuch (FE) variant remains poorly characterized. This natural history study of 240 men with HH delineates the clinical presentation, neuroendocrine profile, rate of reversal and genetics of the FE variant. We compared three HH groups: FE (n=38), absent puberty (n=139), and partial puberty (n=63). The FE group had no history of micropenis and 2/38 (5%) had cryptorchidism (

Identifiants

pubmed: 36407308
doi: 10.3389/fendo.2022.1054447
pmc: PMC9666691
doi:

Substances chimiques

Gonadotropins 0

Types de publication

Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

1054447

Subventions

Organisme : NICHD NIH HHS
ID : F32 HD108873
Pays : United States
Organisme : NICHD NIH HHS
ID : P50 HD104224
Pays : United States
Organisme : NCATS NIH HHS
ID : R03 TR003533
Pays : United States
Organisme : NICHD NIH HHS
ID : R37 HD043341
Pays : United States

Informations de copyright

Copyright © 2022 Dwyer, Stamou, McDonald, Anghel, Cox, Salnikov, Plummer, Seminara and Balasubramanian.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Références

Endocr J. 2003 Dec;50(6):733-7
pubmed: 14709845
Medicina (B Aires). 2015;75(1):53-8
pubmed: 25637904
J Clin Endocrinol Metab. 2022 Jul 14;107(8):2228-2242
pubmed: 35574646
J Clin Invest. 1973 Oct;52(10):2617-28
pubmed: 4729055
J Clin Invest. 1974 Sep;54(3):609-18
pubmed: 4852310
Front Endocrinol (Lausanne). 2019 Jul 23;10:489
pubmed: 31396156
Curr Opin Endocr Metab Res. 2020 Oct;14:15-21
pubmed: 32524038
J Clin Endocrinol Metab. 2022 Jun 16;107(7):1965-1975
pubmed: 35323957
Andrology. 2014 Nov;2(6):794-808
pubmed: 25271205
Nat Rev Endocrinol. 2015 Sep;11(9):547-64
pubmed: 26194704
Curr Protoc Bioinformatics. 2013;43:11.10.1-11.10.33
pubmed: 25431634
Endocr Rev. 2019 Apr 1;40(2):669-710
pubmed: 30698671
J Clin Endocrinol Metab. 1999 Mar;84(3):1028-36
pubmed: 10084591
J Endocrinol Invest. 2021 Nov;44(11):2445-2454
pubmed: 33738751
N Engl J Med. 2004 Dec 16;351(25):2619-25
pubmed: 15602022
Physiol Behav. 1984 Mar;32(3):489-502
pubmed: 6463130
Neuroendocrinology. 2009;90(3):260-8
pubmed: 19829004
Eur J Endocrinol. 2016 Jun;174(6):R267-74
pubmed: 26792935
N Engl J Med. 2007 Aug 30;357(9):863-73
pubmed: 17761590
J Clin Endocrinol Metab. 2002 Sep;87(9):4128-36
pubmed: 12213860
Eur J Endocrinol. 2007 Jan;156(1):105-11
pubmed: 17218732
Nature. 2020 May;581(7809):434-443
pubmed: 32461654
J Clin Endocrinol Metab. 2013 Nov;98(11):E1790-5
pubmed: 24037890
N Engl J Med. 2009 Nov 5;361(19):1856-63
pubmed: 19890128
Hum Genet. 2021 Jan;140(1):77-111
pubmed: 32200437
J Clin Invest. 2018 May 1;128(5):1787-1792
pubmed: 29584617
J Clin Endocrinol Metab. 2014 Mar;99(3):861-70
pubmed: 24423288
Fertil Steril. 2022 Feb;117(2):246-251
pubmed: 34986984
Hum Reprod. 2006 Apr;21(4):1033-40
pubmed: 16396935
Best Pract Res Clin Endocrinol Metab. 2015 Jan;29(1):91-103
pubmed: 25617175
Lancet. 1997 Jul 26;350(9073):263-4
pubmed: 9242808
Clin Endocrinol (Oxf). 2018 Dec;89(6):712-718
pubmed: 30194850
J Clin Endocrinol Metab. 2010 Jun;95(6):3019-27
pubmed: 20382682

Auteurs

Andrew A Dwyer (AA)

Boston College William F. Connell School of Nursing, Chestnut Hill, MA, United States.
Massachusetts General Hospital - Harvard Center for Reproductive Medicine, Massachusetts General Hospital, Boston, MA, United States.

Maria Stamou (M)

Massachusetts General Hospital - Harvard Center for Reproductive Medicine, Massachusetts General Hospital, Boston, MA, United States.
Reproductive Endocrine Unit, Massachusetts General Hospital, Boston, MA, United States.

Isabella R McDonald (IR)

Boston College William F. Connell School of Nursing, Chestnut Hill, MA, United States.
Reproductive Endocrine Unit, Massachusetts General Hospital, Boston, MA, United States.

Ella Anghel (E)

Boston College Lynch School of Education and Human Development, Department of Measurement, Evaluation, Statistics and Assessment, Chestnut Hill, MA, United States.

Kimberly H Cox (KH)

Massachusetts General Hospital - Harvard Center for Reproductive Medicine, Massachusetts General Hospital, Boston, MA, United States.
Reproductive Endocrine Unit, Massachusetts General Hospital, Boston, MA, United States.

Kathryn B Salnikov (KB)

Massachusetts General Hospital - Harvard Center for Reproductive Medicine, Massachusetts General Hospital, Boston, MA, United States.
Reproductive Endocrine Unit, Massachusetts General Hospital, Boston, MA, United States.

Lacey Plummer (L)

Massachusetts General Hospital - Harvard Center for Reproductive Medicine, Massachusetts General Hospital, Boston, MA, United States.
Reproductive Endocrine Unit, Massachusetts General Hospital, Boston, MA, United States.

Stephanie B Seminara (SB)

Massachusetts General Hospital - Harvard Center for Reproductive Medicine, Massachusetts General Hospital, Boston, MA, United States.
Reproductive Endocrine Unit, Massachusetts General Hospital, Boston, MA, United States.

Ravikumar Balasubramanian (R)

Massachusetts General Hospital - Harvard Center for Reproductive Medicine, Massachusetts General Hospital, Boston, MA, United States.
Reproductive Endocrine Unit, Massachusetts General Hospital, Boston, MA, United States.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH